{
    "pmcid": "11562025",
    "qa_pairs": {
        "How do some variants like BA.2.86 and JN.1 differ in their interaction with ACE2 compared to other variants?": [
            "They show reduced dependency on ACE2 for entry, despite having increased ACE2 binding affinity.",
            "They have decreased ACE2 binding affinity and increased dependency on ACE2 for entry.",
            "They exhibit no change in ACE2 binding affinity but have increased dependency on ACE2 for entry.",
            "They show increased ACE2 binding affinity and decreased dependency on ACE2 for entry."
        ],
        "What does the study suggest about the combination of mutations across the spike protein?": [
            "The combination of mutations enhances neutralization resistance more than individual mutations alone.",
            "Individual mutations are more effective at conferring resistance than combinations.",
            "Combinations of mutations have no significant impact on neutralization resistance.",
            "Only mutations within the RBD contribute to enhanced resistance, not combinations across the spike."
        ],
        "What is one of the key strategies suggested for designing SARS-CoV-2 nanobody binders?": [
            "Targeting conserved regions within the spike protein that are less likely to mutate.",
            "Focusing solely on the RBD to ensure high specificity.",
            "Developing nanobodies that only bind to the N-terminal domain (NTD).",
            "Creating nanobodies that exclusively mimic the ACE2 receptor."
        ],
        "What is the primary focus of the paper titled 'Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions'?": [
            "The role of specific mutations in the SARS-CoV-2 spike protein in contributing to neutralization resistance.",
            "The development of vaccines targeting the SARS-CoV-2 spike protein.",
            "The epidemiological spread of SARS-CoV-2 variants across different regions.",
            "The effectiveness of current antiviral drugs against SARS-CoV-2."
        ],
        "Which specific mutations in the receptor binding domain (RBD) are highlighted as significantly reducing neutralization by altering antibody binding sites?": [
            "E484K, G446S, and Q493R",
            "D614G, N501Y, and P681H",
            "K417N, L452R, and T478K",
            "N440K, S477N, and A701V"
        ]
    }
}